| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00754013 Details | 2020-01-28 Interventional | 3 | 9 | Donepezil Cognitive Dysfu… Down Syndrome Syndrome | Sufficient evidence of efficacy not met. Due to the study terminating early,only 9 subjects were enrolled and these subjects receive only limited exposure to study medications with no subject reaching his/her maximum targeted dose. Therefore,the planned efficacy criteria were not analyzed. | |||
| NCT00746486 2007-004040-70 Details | 2020-01-28 Interventional | 3 | 62 | Budesonide Fibrosis Liver Cirrhosis Liver Cirrhosis… Primary Biliary… | Study stopped based on the recommendation of the IDMC after a planned Interim Analysis - | |||
| NCT03961048 Details | 2020-01-27 Interventional | 4 | 0 | Pharmaceutical … Ropivacaine Chest Pain Pain, Postopera… Pain, Chest | Change in hospital protocol - | |||
| NCT03865563 Details | 2020-01-27 Interventional | 1 | 0 | Ethiodized Oil Gemcitabine Pancreatic Neop… Pancreatic Aden… | We need to make significant adjustments to proposed drug and its delivery method - | |||
| NCT00899431 Details | 2020-01-27 Interventional | 2 | 39 | Allopurinol Antilymphocyte … Bendamustine Hy… Fludarabine Fludarabine pho… Lenalidomide Rituximab Thymoglobulin Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Terminated per PI's request at the time of continuing review - | |||
| NCT02311764 Details | 2020-01-23 Interventional | 2 | 16 | Carboplatin Prostatic Neopl… Prostatic Neopl… | - - | |||
| NCT03774745 Details | 2020-01-22 Interventional | 1/2 | 12 | Mifepristone Progesterone Pregnancy, Unwa… | Safety Early termination for safety reasons leading to small numbers of subjects analyzed for efficacy outcomes. Imbalance in participant characteristics due to early termination. | |||
| NCT03168594 Details | 2020-01-22 Interventional | 2 | 66 | Cisplatin Etoposide Irinotecan Carcinoma Carcinoma, Neur… Neuroendocrine … | The enrollment was terminated early because the premature analysis found similar response in
the two arms. - | |||
| NCT02508935 Details | 2020-01-22 Interventional | 4 | 23 | Acetaminophen, … Acute Pain | Business decision - | |||
| NCT02274506 Details | 2020-01-22 Interventional | 1 | 0 | Cyclophosphamid… Fludarabine Fludarabine pho… Leukemia Lymphoma Blood And Marro… | PI's response to ePAAC, has withdrawn the protocol acknowledging the PI's action. - | |||
| NCT02018419 Details | 2020-01-22 Interventional | 1/2 | [5 Refs] | 0 | Vaccines Breast Neoplasm… Metastatic Brea… | changing indication from breast cancer to metastatic colorectal cancer - | ||
| NCT01887587 Details | 2020-01-22 Interventional | 1 | 5 | Dexamethasone Doxorubicin Ixazomib Vincristine Acute Disease Leukemia Leukemia, Lymph… Lymphoma Lymphoma, Non-H… Precursor Cell … Mixed Phenotype… Relapsed or Ref… Relapsed or Ref… | SAE- risk of overall protocol treatment outweighs benefits - | |||
| NCT03230864 Details | 2020-01-21 Interventional | 3 | 119 | Olanzapine Risperidone Schizophrenia Schizophrenia, … Treatment-resis… | New data; the study was terminated based on new efficacy data from another study The study was terminated early and hence the statistical analysis was conducted on a smaller sample size than originally planned. | |||
| NCT03654417 Details | 2020-01-18 Interventional | 4 | 37 | Lidocaine Any Condition R… | interim analysis produced significant results, so we ended enrollment unblinded patients and providers, prior experience with vulvar biopsy may be biasing, pre-procedure anxiety may be biased because posed after randomization, no gold standard for pain assessment | |||
| NCT02215174 Details | 2020-01-18 Interventional | 1 | 21 | Rosuvastatin Ca… Statin Pharmaco… | IRB approval expired - | |||
| NCT03608501 Details | 2020-01-14 Interventional | 2 | 0 | Dexamethasone Ixazomib Thalidomide Multiple Myelom… Neoplasms, Plas… | Business decision (no safety or efficacy concerns) - | |||
| NCT02599649 Details | 2020-01-14 Interventional | 2 | 10 | Azacitidine Nivolumab Myelodysplastic… Preleukemia Leukemia | Enrollment was stopped after the sponsor's decision not to pursue the development of lirilumab
for myeloid malignancies. - | |||
| NCT03383588 Details | 2020-01-13 Interventional | 2 | 26 | Bupivacaine Epinephrine Fentanyl Morphine Pain, Referred | study was published during initial recruitment that showed no difference Early termination leading to small numbers of subjects and Technical problems with measurement leading to unreliable or uninterpretable data; Study terminated early secondary to similar study published showing no difference in outcomes | |||
| NCT02754362 Details | 2020-01-13 Interventional | 2 | 0 | Adjuvants, Immu… Bevacizumab Keyhole-limpet … Poly ICLC Glioblastoma Glioma | Due to personnel changes / departure of Dr. Chi. - | |||
| NCT02556203 2015-001975-30 Details | 2020-01-13 Interventional | 3 | 1653 | Aspirin Clopidogrel Rivaroxaban Vitamin K Transcatheter A… | Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator - |